Analysed BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) News Sources
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
18-06-2026
yahoo.com
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
22-07-2026
yahoo.com
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
27-07-2026
yahoo.com
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
13-08-2026
yahoo.com
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
13-08-2026
yahoo.com
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
14-08-2026
yahoo.com
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
18-08-2026
yahoo.com
What is the current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is $5.1.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is $-0.09.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is -1.7341%.
What is the most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is 62 out of 100.
What is the most recent average sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is .
SEC-8K** Filing Available For BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.